Drug Trial Radar · NCT07030257
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Aug 15, 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- Tasca TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests
Conditions
- Solid Tumor Malignancies
- Colorectal Carcinoma
- Small Cell Lung Cancer ( SCLC )
- Head and Neck (HNSCC)
- Bladder Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383Drug
Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Determine the maximum tolerated dose (MTD)Time frame: 21 days
- Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor typesTime frame: From enrollment through study completion, an average of 1 year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
Florida Cancer Specialists-Lake Nona
Orlando, Florida · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
NEXT Oncology - Dallas
Dallas, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.